Lupus & antiphospholipid syndrome
COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, immunogenicity, flares and acceptance
Authors' conclusion
Among SLE patients, post-vaccine COVID-19 infections, severe flares, and adverse events were infrequent, while pooled seropositivity and acceptance were high, with significant heterogeneity.
Study context
- Population
- Individuals with SLE vaccinated against COVID-19; PubMed, EMBASE, CENTRAL and Scopus until 8 June 202232 studies (34 reports)
- Participants
- 8,269 individuals
- Outcome
- Pooled seropositivity rate
Methodological detailsPRISMA 2020, risk of bias assessed
- PRISMA 2020
- Risk of bias assessed
Pooled result
As reported in the abstract
Pooled seropositivity rate (17 studies, 976 patients)
81.1%
95% CI 72.6, 88.5%, I2 = 85%P < 0.01
Further pooled results
Post-vaccine COVID-19 infections
- Range across 6 studies (5065 patients)
- 0 to 17%
Cellular immunogenicity
- Evaluated in 5 studies (112 patients)
Pooled vaccine acceptance rate
- Pooled acceptance (8 studies, 1348 patients)
- 67.0% (95% CI: 45.2, 85.6%, I2=98%, P < 0.01)
- Greater acceptance in older patients
Safety
Severe adverse events (20 studies, 3853 patients)
- Severe adverse events were infrequent
Moderate to severe lupus flares (13 studies, 2989 patients)
- Moderate to severe lupus flares were infrequent
Original publication
COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, immunogenicity, flares and acceptance. Rheumatology (Oxford). Published 22 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →